11. Anti-Angiogenesis Agents
D.J. Rhee et al., Ophthalmologic Drug Guide, 2nd ed., DOI 10.1007/978-1-4419-7621-5_11,
Springer ScienceþBusiness Media, LLC 2011
|
|
|
|
|
102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Drug |
Trade |
Preparation |
Usual Dose |
Notes |
||
|
|
|
|
|
|
|
verteporfin |
Visudyne |
Soln, 2 mg/ml (supplied as |
See appendix 7 For photodynamic therapy for subfoveal choroidal |
|||
|
|
15 mg of lyophilized powder |
|
neovascularization |
||
|
|
to be diluted in 7.5 ml of |
|
|
|
|
|
|
sterile water) |
|
|
|
|
pegaptanib |
Macugen |
0.3 mg intravitreal Q6 weeks |
|
(N Engl J Med 2004; 351: 2805–16.) |
||
sodium |
|
|
|
Note: Approved by the FDA for all subtypes |
||
|
|
|
|
(predominantly classic, minimally classic, occult) |
||
|
|
|
|
of CNV secondary to age-related macular |
||
|
|
|
|
degeneration (AMD) |
||
ranibizumab |
Lucentis |
0.5 mg intravitreal Qmonth |
|
Approved for the treatment of all subtypes of CNV |
||
|
|
|
|
secondary to AMD and for treatment of macular |
||
|
|
|
|
edema secondary to BRVO and CRVO |
||
bevacizumab |
Avastin |
1.25 mg intravitreal |
|
Intravitreal injection of bevacizumab is an off-label |
||
|
|
|
|
use of the drug. We do not yet have results of the |
||
|
|
|
|
randomized clinical trial of its use for AMD at |
||
|
|
|
|
the time of the writing of this book but it is widely |
||
|
|
|
|
used for this indication. It is also widely used for |
||
|
|
|
|
macular edema of various etiologies and retinal |
||
|
|
|
|
and iris neovascularization |
||
triamcinolone |
Kenalog |
4.0 mg intravitreal |
|
Intravitreal injection of triamcinolone acetate has |
||
acetate |
Triesence |
20–40 mg sub-Tenon’s |
|
been used in the treatment of macular edema of |
||
|
|
|
|
various etiologies and for uveitis |
||
|
|
|
|
|
|
|